Efficacy, Tolerability, and Safety of Once-Daily Atomoxetine Hydrochloride Versus Placebo in Russian Children and Adolescents With Attention-Deficit/Hyperactivity Disorder

NCT00386581 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

105

Enrollment

INDUSTRY

Sponsor class

Conditions

Attention Deficit Disorder With Hyperactivity

Interventions

DRUG: atomoxetine
DRUG: placebo

Sponsor

Eli Lilly and Company